Market Closed -
London S.E.
16:35:13 29/04/2024 BST
|
5-day change
|
1st Jan Change
|
1.35
GBX
|
0.00%
|
|
-5.26%
|
-79.85%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
35.51
|
209.8
|
74.69
|
96.06
|
18.29
|
10.56
|
10.56
|
-
|
Enterprise Value (EV)
1 |
25.73
|
205.7
|
71.78
|
84.1
|
18.29
|
13.38
|
27.3
|
22.75
|
P/E ratio
|
-15.3
x
|
-22.4
x
|
-31.8
x
|
-4.94
x
|
-0.41
x
|
-0.34
x
|
-0.78
x
|
4.22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2.99
x
|
292
x
|
7.19
x
|
63.2
x
|
4.09
x
|
0.85
x
|
0.29
x
|
0.15
x
|
EV / Revenue
|
2.17
x
|
286
x
|
6.91
x
|
55.4
x
|
4.09
x
|
1.08
x
|
0.75
x
|
0.32
x
|
EV / EBITDA
|
-9.14
x
|
-32.1
x
|
130
x
|
-4.74
x
|
-0.78
x
|
-0.58
x
|
-3.05
x
|
1.42
x
|
EV / FCF
|
-
|
-38
x
|
-50.4
x
|
-4.92
x
|
-
|
-0.46
x
|
-2.03
x
|
4.38
x
|
FCF Yield
|
-
|
-2.63%
|
-1.98%
|
-20.3%
|
-
|
-219%
|
-49.2%
|
22.8%
|
Price to Book
|
-
|
-
|
2.47
x
|
2.34
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
116,426
|
117,189
|
117,620
|
215,874
|
259,388
|
782,056
|
782,056
|
-
|
Reference price
2 |
0.3050
|
1.790
|
0.6350
|
0.4450
|
0.0705
|
0.0135
|
0.0135
|
0.0135
|
Announcement Date
|
03/04/19
|
21/05/20
|
29/04/21
|
30/06/22
|
27/04/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
11.88
|
0.719
|
10.39
|
1.519
|
4.467
|
12.37
|
36.3
|
71.13
|
EBITDA
1 |
-2.814
|
-6.414
|
0.551
|
-17.74
|
-23.34
|
-22.9
|
-8.964
|
15.99
|
EBIT
1 |
-5.168
|
-9.035
|
-2.154
|
-19.95
|
-25.71
|
-23.31
|
-11.63
|
6.947
|
Operating Margin
|
-43.5%
|
-1,256.61%
|
-20.74%
|
-1,313.5%
|
-575.46%
|
-188.38%
|
-32.04%
|
9.77%
|
Earnings before Tax (EBT)
1 |
-5.153
|
-9.066
|
-1.886
|
-19.56
|
-40.08
|
-25.48
|
-12.71
|
11.53
|
Net income
1 |
-1.794
|
-8.8
|
-2.63
|
-19.34
|
-40.44
|
-27
|
-10.9
|
11.8
|
Net margin
|
-15.1%
|
-1,223.92%
|
-25.32%
|
-1,272.94%
|
-905.4%
|
-218.19%
|
-30.03%
|
16.59%
|
EPS
2 |
-0.0200
|
-0.0800
|
-0.0200
|
-0.0900
|
-0.1700
|
-0.0392
|
-0.0174
|
0.003200
|
Free Cash Flow
1 |
-
|
-5.416
|
-1.423
|
-17.11
|
-
|
-29.37
|
-13.42
|
5.198
|
FCF margin
|
-
|
-753.27%
|
-13.7%
|
-1,126.4%
|
-
|
-237.34%
|
-36.98%
|
7.31%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
32.5%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
44.05%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/04/19
|
21/05/20
|
29/04/21
|
30/06/22
|
27/04/23
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2022 S1
|
2023 S1
|
---|
Net sales
1 |
8.919
|
2.031
|
4.334
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-
|
-11.72
|
-11.54
|
Operating Margin
|
-
|
-577.25%
|
-266.29%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
16/09/20
|
08/09/22
|
28/09/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
2.82
|
16.7
|
12.2
|
Net Cash position
1 |
9.78
|
4.1
|
2.91
|
12
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.1233
x
|
-1.867
x
|
0.7624
x
|
Free Cash Flow
1 |
-
|
-5.42
|
-1.42
|
-17.1
|
-
|
-29.4
|
-13.4
|
5.2
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-8.43%
|
-54.2%
|
-
|
-
|
-
|
131%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
0.2600
|
0.1900
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-0
|
-0.0300
|
-0.0100
|
-0.0800
|
-
|
-0.0500
|
-0.0200
|
0.0200
|
Capex
1 |
3
|
1.35
|
0.02
|
0.37
|
-
|
0.94
|
0.7
|
0.74
|
Capex / Sales
|
25.24%
|
187.76%
|
0.22%
|
24.49%
|
-
|
7.63%
|
1.94%
|
1.04%
|
Announcement Date
|
03/04/19
|
21/05/20
|
29/04/21
|
30/06/22
|
27/04/23
|
-
|
-
|
-
|
Last Close Price
0.0135
GBP Average target price
0.02
GBP Spread / Average Target +48.15% Consensus |
1st Jan change
|
Capi.
|
---|
| -79.85% | 13.15M | | -2.93% | 103B | | +1.36% | 95.28B | | +1.46% | 22.15B | | -16.05% | 21.02B | | -8.58% | 18.15B | | -38.74% | 16.73B | | -13.25% | 16.05B | | +4.87% | 13.68B | | +33.03% | 12.17B |
Bio Therapeutic Drugs
|